iShares Biotechnology ETF
520 hedge funds and large institutions have $5.06B invested in iShares Biotechnology ETF in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 179 increasing their positions, 186 reducing their positions, and 76 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
520
Holders Change
-2
Holders Change %
-0.38%
% of All Funds
12.96%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.5%
New
76
Increased
179
Reduced
186
Closed
76
Calls
$496M
Puts
$763M
Net Calls
-$267M
Net Calls Change
+$81.9M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$191M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$160M |
| 3 |
Morgan Stanley
New York
|
+$73M |
| 4 |
JPMorgan Chase & Co
New York
|
+$72M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$69.2M |
Top Sellers
| 1 |
N
Natixis
Paris,
France
|
-$39.9M |
| 2 |
RIG
RiverFront Investment Group
Richmond,
Virginia
|
-$35.6M |
| 3 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$31.5M |
| 4 |
Jane Street
New York
|
-$30.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$30.1M |
